The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery.
The Roux-en-Y gastric bypass (RYGBP) and the biliopancreatic diversion (BPD) induce long-term control of type 2 diabetes in morbidly obese individuals. The reasons for such an effect on glycemic metabolism are thought to be secondary to reduced food intake, weight loss and modifications of the enteroinsular axis which is impaired in type 2 diabetic patients. Both GLP-1 and GIP have an impaired secretin effect in type 2 diabetics, and surgery can restore this function. GIP is a peptide secreted by the duodenal K-cells in response to ingested fat and carbohydrate. In obese type 2 diabetes patients, its receptor on beta-cells is down-regulated. GLP-1 is a peptide secreted by the gut L-cells, and, in type 2 diabetes, its secretion is impaired. Both RYGBP and BPD provide durable GLP-1 delivery, both during fasting and after meal ingestion, inducing L-cell stimulation by early arrival of nutrients in the distal ileum. The secretion of GLP-1 influences glucose metabolism by inhibiting glucagon secretion, stimulating insulin secretion, delaying gastric emptying and stimulating glycogenogenesis. In conclusion, the early arrival of a meal in the terminal ileum seems to be the common feature of both operations that leads to an improvement in glycemic metabolism and to resolution of type 2 diabetes.
Patriti
Alberto
A
Department of Surgery, University of Perugia, Policlinico Monteluce, Via Brunamonti, 06122 Perugia, Italy.
Facchiano
Enrico
E
Sanna
Andrea
A
Gullà
Nino
N
Donini
Annibale
A
D001786:Blood Glucose / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000503:physiopathology* / Q000601:surgery*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D015536:Down-Regulation / Q000502:physiology; D015390:Gastric Bypass; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism / Q000502:physiology*; D005934:Glucagon / Q000378:metabolism / Q000502:physiology*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007082:Ileum / Q000503:physiopathology; D007328:Insulin / Q000097:blood*; D007333:Insulin Resistance / Q000502:physiology; D009765:Obesity; D009767:Obesity, Morbid / Q000503:physiopathology / Q000601:surgery; D010179:Pancreas / Q000503:physiopathology; D010446:Peptide Fragments / Q000378:metabolism / Q000502:physiology*; D019518:Postprandial Period / Q000502:physiology; D011498:Protein Precursors / Q000378:metabolism / Q000502:physiology*
D001786:Blood Glucose; D007328:Insulin; D010446:Peptide Fragments; D011498:Protein Precursors; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon